JPH11507378A - 酸素飽和状態（ｏｘｇｅｎａｔｉｏｎ ｓｔａｔｕｓ）をモニターすることによって簡便化された血液希釈法 - Google Patents
酸素飽和状態（ｏｘｇｅｎａｔｉｏｎ ｓｔａｔｕｓ）をモニターすることによって簡便化された血液希釈法Info
- Publication number
- JPH11507378A JPH11507378A JP9502135A JP50213597A JPH11507378A JP H11507378 A JPH11507378 A JP H11507378A JP 9502135 A JP9502135 A JP 9502135A JP 50213597 A JP50213597 A JP 50213597A JP H11507378 A JPH11507378 A JP H11507378A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- patient
- oxygen
- biocompatible
- oxygen saturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 275
- 239000001301 oxygen Substances 0.000 title claims abstract description 274
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 273
- 238000000034 method Methods 0.000 title claims abstract description 96
- 206010059484 Haemodilution Diseases 0.000 title claims abstract description 45
- 238000012544 monitoring process Methods 0.000 title description 5
- 239000008280 blood Substances 0.000 claims abstract description 265
- 210000004369 blood Anatomy 0.000 claims abstract description 262
- 238000001356 surgical procedure Methods 0.000 claims abstract description 48
- 206010061216 Infarction Diseases 0.000 claims abstract description 32
- 230000007574 infarction Effects 0.000 claims abstract description 32
- 210000000056 organ Anatomy 0.000 claims abstract description 28
- 208000028867 ischemia Diseases 0.000 claims abstract description 23
- 230000004044 response Effects 0.000 claims abstract description 18
- 239000000839 emulsion Substances 0.000 claims description 59
- 102000001554 Hemoglobins Human genes 0.000 claims description 57
- 108010054147 Hemoglobins Proteins 0.000 claims description 57
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 34
- 239000012530 fluid Substances 0.000 claims description 24
- 238000001990 intravenous administration Methods 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- 239000000969 carrier Substances 0.000 claims description 16
- 208000010125 myocardial infarction Diseases 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000007789 gas Substances 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 210000001147 pulmonary artery Anatomy 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 238000010241 blood sampling Methods 0.000 claims description 4
- 238000003113 dilution method Methods 0.000 claims description 3
- 230000000287 tissue oxygenation Effects 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims 3
- 230000000925 erythroid effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 48
- 210000003743 erythrocyte Anatomy 0.000 description 44
- 239000000203 mixture Substances 0.000 description 31
- 230000000747 cardiac effect Effects 0.000 description 25
- 239000003633 blood substitute Substances 0.000 description 22
- 238000009792 diffusion process Methods 0.000 description 19
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 229960001217 perflubron Drugs 0.000 description 17
- 238000005534 hematocrit Methods 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000084 colloidal system Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000036284 oxygen consumption Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 238000006213 oxygenation reaction Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- -1 C10F18 (“F-decalin” Chemical class 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 3
- 230000035761 normovolemia Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JTYRBFORUCBNHJ-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br JTYRBFORUCBNHJ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 208000036064 Surgical Blood Loss Diseases 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 208000003441 Transfusion reaction Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- 229940068998 egg yolk phospholipid Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- LRMQIJUOLGKFKS-UHFFFAOYSA-N perfluoro-1,3-dimethyladamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(C(F)(F)F)C(F)(F)C2(C(F)(F)F)C3(F)F LRMQIJUOLGKFKS-UHFFFAOYSA-N 0.000 description 2
- JAJLKEVKNDUJBG-UHFFFAOYSA-N perfluorotripropylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F JAJLKEVKNDUJBG-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000008288 physiological mechanism Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- VPQQZKWYZYVTMU-UHFFFAOYSA-N 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,7-pentadecafluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br VPQQZKWYZYVTMU-UHFFFAOYSA-N 0.000 description 1
- SYVYTZLRTMPUCD-UHFFFAOYSA-N 1-chloro-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Cl SYVYTZLRTMPUCD-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical group [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- ZJCFOZHHYJVNNP-UHFFFAOYSA-N F[C]Br Chemical compound F[C]Br ZJCFOZHHYJVNNP-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 238000001982 He+-excited Auger electron spectroscopy Methods 0.000 description 1
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 1
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940092232 albutein Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000004555 blood preservation Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940064366 hespan Drugs 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000010555 moderate anemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 108010014241 oxypolygelatine Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UIOCPFVEDHPJES-UHFFFAOYSA-N perfluoro-4-methylquinolizidine Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(C(F)(F)F)(F)N21 UIOCPFVEDHPJES-UHFFFAOYSA-N 0.000 description 1
- ZYYBBMCBAFICKK-UHFFFAOYSA-N perfluoro-N-cyclohexylpyrrolidine Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)N1C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F ZYYBBMCBAFICKK-UHFFFAOYSA-N 0.000 description 1
- FRZFEPXEUZSBLA-UHFFFAOYSA-N perfluoroadamantane Chemical compound FC1(F)C(C2(F)F)(F)C(F)(F)C3(F)C(F)(F)C1(F)C(F)(F)C2(F)C3(F)F FRZFEPXEUZSBLA-UHFFFAOYSA-N 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- 125000005007 perfluorooctyl group Chemical group FC(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)* 0.000 description 1
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 108010088880 plasmagel Proteins 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000000520 progressive familial heart block Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/484,166 US5865784A (en) | 1995-06-07 | 1995-06-07 | Method of hemodilution facilitated by monitoring oxygenation status |
| US08/484,166 | 1995-06-07 | ||
| PCT/US1996/009990 WO1996040222A1 (en) | 1995-06-07 | 1996-06-07 | Hemodilution facilitated by monitoring oxygenation status |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11507378A true JPH11507378A (ja) | 1999-06-29 |
| JPH11507378A5 JPH11507378A5 (enExample) | 2004-07-29 |
Family
ID=23923030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9502135A Ceased JPH11507378A (ja) | 1995-06-07 | 1996-06-07 | 酸素飽和状態（ｏｘｇｅｎａｔｉｏｎ ｓｔａｔｕｓ）をモニターすることによって簡便化された血液希釈法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US5865784A (enExample) |
| EP (1) | EP0831890A1 (enExample) |
| JP (1) | JPH11507378A (enExample) |
| KR (1) | KR19990022355A (enExample) |
| CN (2) | CN1720904A (enExample) |
| AU (1) | AU717317B2 (enExample) |
| CA (1) | CA2222066A1 (enExample) |
| HU (1) | HUP9802266A3 (enExample) |
| IL (1) | IL122239A0 (enExample) |
| NO (1) | NO975318L (enExample) |
| PL (1) | PL323937A1 (enExample) |
| WO (1) | WO1996040222A1 (enExample) |
| ZA (1) | ZA964656B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005511504A (ja) * | 2001-09-10 | 2005-04-28 | バイオピュア コーポレーション | 貯蔵された赤血球による酸素輸送の改善方法 |
| JP4773098B2 (ja) * | 2003-01-23 | 2011-09-14 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 呼気を用いる静脈薬剤濃度をモニタするための方法および装置 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6676900B1 (en) | 1994-12-09 | 2004-01-13 | Therox, Inc. | Method for the preparation and delivery of gas-enriched fluids |
| US6180059B1 (en) * | 1995-06-05 | 2001-01-30 | Therox, Inc. | Method for the preparation and delivery of gas-enriched fluids |
| US5865784A (en) | 1995-06-07 | 1999-02-02 | Alliance Pharmaceutical Corp. | Method of hemodilution facilitated by monitoring oxygenation status |
| WO1999053287A2 (en) * | 1998-04-09 | 1999-10-21 | California Institute Of Technology | Electronic techniques for analyte detection |
| GB2343679A (en) * | 1998-11-16 | 2000-05-17 | Alison Miriam Davies | Autologous transplantation and method for making cells dormant |
| US6884228B2 (en) | 2001-03-06 | 2005-04-26 | Baxter International Inc. | Automated system adaptable for use with different fluid circuits |
| US6706008B2 (en) | 2001-03-06 | 2004-03-16 | Baxter International Inc. | Automated system and method for withdrawing compounds from blood |
| US6808503B2 (en) | 2001-03-06 | 2004-10-26 | Baxter International Inc. | Automated system and method for pre-surgical blood donation and fluid replacement |
| US6582386B2 (en) | 2001-03-06 | 2003-06-24 | Baxter International Inc. | Multi-purpose, automated blood and fluid processing systems and methods |
| US20070160645A1 (en) * | 2001-10-25 | 2007-07-12 | Jakob Vinten-Johansen | PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs |
| ATE411058T1 (de) | 2001-10-25 | 2008-10-15 | Univ Emory | Katheter für modifizierte perfusion |
| US7241307B2 (en) * | 2001-12-31 | 2007-07-10 | Medcool, Inc. | Method and apparatus for managing temperature in a patient |
| EP2034959B1 (en) * | 2006-05-22 | 2017-01-11 | Alliance Pharmaceutical Corp | Optimized fluorocarbon emulsions for blood substitutes and other therapeutic uses |
| US20100093873A1 (en) * | 2008-10-02 | 2010-04-15 | Goldfischer Sidney L | Methods of improving therapy of perfluorocarbons (PFC) |
| US8636952B2 (en) * | 2008-12-04 | 2014-01-28 | Therox, Inc. | System for enriching a bodily fluid with a gas having a removable gas-enrichment device with an information recording element |
| US20100143190A1 (en) * | 2008-12-04 | 2010-06-10 | Therox, Inc. | System for enriching a bodily fluid with a gas having occlusion detection capabilities |
| US8192384B2 (en) * | 2008-12-04 | 2012-06-05 | Therox, Inc. | System for enriching a bodily fluid with a gas having a dual-function power switch mechanism |
| US8246564B2 (en) * | 2008-12-04 | 2012-08-21 | Therox, Inc. | System for enriching a bodily fluid with a gas having automated priming capabilities |
| US20100143192A1 (en) * | 2008-12-04 | 2010-06-10 | Therox, Inc. | Method and device for combined detection of bubbles and flow rate in a system for enriching a bodily fluid with a gas |
| US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US8048856B1 (en) | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
| US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
| US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| CN108380965B (zh) * | 2013-04-04 | 2021-02-19 | 米沃奇电动工具公司 | 电动工具 |
| GB2540724A (en) | 2015-03-06 | 2017-02-01 | Spectrum Medical Ltd | Blood analysis apparatus and method |
| FR3097770B1 (fr) * | 2019-06-27 | 2024-03-01 | I Sep | Système et procédé de traitement de liquide hémorragique pour de l’autotransfusion |
| CN111135360A (zh) * | 2020-01-21 | 2020-05-12 | 广州弘大医疗科技有限公司 | 一种右心辅助装置及其控制方法 |
| CN116370633A (zh) * | 2023-04-21 | 2023-07-04 | 中国药科大学 | 一种包载全氟己烷和抗氧化剂的纳米脂质制剂及其制备方法与制备治疗心肌梗死药物的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3482575A (en) | 1967-02-16 | 1969-12-09 | Single Cell Research Foundatio | Method for the extracorporeal oxygenation of blood |
| US3958014A (en) | 1970-09-05 | 1976-05-18 | The Green Cross Corporation | Process for preparing injection-purpose fluorocarbon emulsion capable of carrying oxygen |
| US3975512A (en) * | 1970-12-21 | 1976-08-17 | University Of Illinois Foundation | Non-toxic brominated perfluorocarbons radiopaque agents |
| US4073879A (en) * | 1974-08-26 | 1978-02-14 | University Of Illinois Foundation | Brominated perfluorocarbon radiopaque agents |
| DE2754894C2 (de) | 1977-12-09 | 1983-10-13 | Fresenius AG, 6380 Bad Homburg | Vorrichtung zum Bilanzieren einer einem Patienten entnommenen Flüssigkeit mit einer Ersatzflüssigkeit |
| DE3049665T1 (de) | 1979-06-25 | 1982-03-18 | Suntech | Use of perfluorocarbon as burn treatment |
| JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4981691A (en) | 1980-04-14 | 1991-01-01 | Thomas Jefferson University | Oxygenated fluorocarbon nutrient solution |
| US4657532A (en) | 1985-07-19 | 1987-04-14 | Thomas Jefferson University | Intra-peritoneal perfusion of oxygenated fluorocarbon |
| FR2515198A1 (fr) | 1981-10-22 | 1983-04-29 | Centre Nat Rech Scient | Microemulsions aqueuses de fluorocarbures indefiniment stables a une temperature donnee, procede d'obtention et application a titre de transporteurs d'oxygene |
| JPS5832829A (ja) | 1981-08-22 | 1983-02-25 | Green Cross Corp:The | 血管造影剤 |
| DE3144705C2 (de) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
| US4425334A (en) | 1982-04-02 | 1984-01-10 | The Regents Of The University Of California | Functional oxygen transport system |
| US4473494A (en) * | 1983-05-04 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Preparation of stroma-free, non-heme protein-free hemoglobin |
| DE3340592A1 (de) * | 1983-11-10 | 1985-05-23 | B. Braun Melsungen Ag, 3508 Melsungen | Konjugate makromolekularer verbindungen an haemoglobine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| JPS60166626A (ja) | 1984-02-09 | 1985-08-29 | Green Cross Corp:The | 血管造影剤 |
| DE3412144A1 (de) * | 1984-03-31 | 1985-10-10 | Biotest Pharma GmbH, 6000 Frankfurt | Verfahren zur herstellung hochgereinigter, stromafreier, hepatitissicherer human- und tierhaemoglobinloesungen |
| US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
| US4927623A (en) | 1986-01-14 | 1990-05-22 | Alliance Pharmaceutical Corp. | Dissolution of gas in a fluorocarbon liquid |
| US5080885A (en) | 1986-01-14 | 1992-01-14 | Alliance Pharmaceutical Corp. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
| US4865836A (en) * | 1986-01-14 | 1989-09-12 | Fluoromed Pharmaceutical, Inc. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
| US4911929A (en) * | 1986-08-29 | 1990-03-27 | The United States Of America As Represented By The Secretary Of The Navy | Blood substitute comprising liposome-encapsulated hemoglobin |
| US4861667A (en) | 1986-12-19 | 1989-08-29 | Asahi Glass Company, Ltd. | Coating composition and coated product |
| GB8710598D0 (en) * | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
| US4861867A (en) * | 1988-02-03 | 1989-08-29 | Baxter International, Inc. | Purified hemoglobin solutions and method for making same |
| US5130230A (en) | 1988-05-02 | 1992-07-14 | Cryomedical Sciences, Inc. | Blood substitute |
| US4911999A (en) | 1988-12-13 | 1990-03-27 | E. I. Du Pont De Nemours And Company | Electrostatic master containing thiourea or thioamide electrostatic decay additive for high speed xeroprinting |
| US5344393A (en) | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
| US5865784A (en) | 1995-06-07 | 1999-02-02 | Alliance Pharmaceutical Corp. | Method of hemodilution facilitated by monitoring oxygenation status |
-
1995
- 1995-06-07 US US08/484,166 patent/US5865784A/en not_active Ceased
-
1996
- 1996-06-05 ZA ZA964656A patent/ZA964656B/xx unknown
- 1996-06-07 CA CA002222066A patent/CA2222066A1/en not_active Abandoned
- 1996-06-07 CN CNA2005100544073A patent/CN1720904A/zh active Pending
- 1996-06-07 EP EP96921501A patent/EP0831890A1/en not_active Withdrawn
- 1996-06-07 PL PL96323937A patent/PL323937A1/xx unknown
- 1996-06-07 WO PCT/US1996/009990 patent/WO1996040222A1/en not_active Ceased
- 1996-06-07 HU HU9802266A patent/HUP9802266A3/hu unknown
- 1996-06-07 CN CN96195920A patent/CN1192155A/zh active Pending
- 1996-06-07 KR KR1019970708835A patent/KR19990022355A/ko not_active Abandoned
- 1996-06-07 AU AU62713/96A patent/AU717317B2/en not_active Ceased
- 1996-06-07 JP JP9502135A patent/JPH11507378A/ja not_active Ceased
- 1996-06-07 IL IL12223996A patent/IL122239A0/xx unknown
-
1997
- 1997-11-19 NO NO975318A patent/NO975318L/no unknown
-
1998
- 1998-06-18 US US09/099,731 patent/US6007774A/en not_active Expired - Fee Related
-
2001
- 2001-02-02 US US09/776,144 patent/USRE38081E1/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005511504A (ja) * | 2001-09-10 | 2005-04-28 | バイオピュア コーポレーション | 貯蔵された赤血球による酸素輸送の改善方法 |
| JP4773098B2 (ja) * | 2003-01-23 | 2011-09-14 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 呼気を用いる静脈薬剤濃度をモニタするための方法および装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU717317B2 (en) | 2000-03-23 |
| HUP9802266A3 (en) | 2001-03-28 |
| AU6271396A (en) | 1996-12-30 |
| NO975318D0 (no) | 1997-11-19 |
| ZA964656B (en) | 1997-02-28 |
| CN1192155A (zh) | 1998-09-02 |
| CN1720904A (zh) | 2006-01-18 |
| US5865784A (en) | 1999-02-02 |
| EP0831890A1 (en) | 1998-04-01 |
| HUP9802266A2 (hu) | 1999-02-01 |
| USRE38081E1 (en) | 2003-04-15 |
| KR19990022355A (ko) | 1999-03-25 |
| IL122239A0 (en) | 1998-04-05 |
| NO975318L (no) | 1998-01-30 |
| PL323937A1 (en) | 1998-04-27 |
| WO1996040222A1 (en) | 1996-12-19 |
| CA2222066A1 (en) | 1996-12-19 |
| US6007774A (en) | 1999-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11507378A (ja) | 酸素飽和状態（ｏｘｇｅｎａｔｉｏｎ ｓｔａｔｕｓ）をモニターすることによって簡便化された血液希釈法 | |
| US5451205A (en) | Facilitated oxygen delivery in conjunction with hemodilution | |
| Fontana et al. | Oxygen consumption and cardiovascular function in children during profound intraoperative normovolemic hemodilution | |
| Goodin et al. | A perfluorochemical emulsion for prehospital resuscitation of experimental hemorrhagic shock: a prospective, randomized, controlled study | |
| WO1991000110A1 (en) | Fluorocarbon emulsions having saturated phospholipid emulsifiers | |
| Lane | Perfluorochemical-based artificial oxygen carrying red cell substitutes | |
| Waxman | Perfluorocarbons as blood substitutes | |
| RU2393849C2 (ru) | Эмульсия перфторорганических соединений медицинского назначения, способ ее приготовления и способ ее применения | |
| CA2315877C (en) | Facilitated oxygen delivery in conjunction with hemodilution | |
| Faithfull et al. | Tissue oxygenation by fluorocarbons | |
| Cefalo et al. | Maternal and fetal effects of exchange transfusion with a red blood cell substitute | |
| CA2085475A1 (en) | Hyperosmotic solutions for isonatremic resuscitation | |
| MXPA97009697A (es) | Hemodulacion facilitada por el monitoreo de la condicion de oxigenacion | |
| AU4264100A (en) | Hemodilution facilitated by mounting oxygenation status | |
| CA2345895A1 (en) | Improved artificial blood fluids | |
| HK1010448B (en) | Facilitated oxygen delivery in conjunction with hemodilution | |
| Marchbank | Fluorocarbon emulsions | |
| Gollan et al. | Experimental study of perfusion of rabbits with fluorocarbon fluid in the acute asanguineous state | |
| Shander et al. | Intraoperative acute normovolemic hemodilution | |
| Ottermann et al. | Experiments with Haemoglobin Solutions | |
| Kim | Anesthetic management of Jehovah's Witness patients | |
| CA2207775A1 (en) | Method for facilitating autologous blood donation and treating oxygen debt | |
| Cabrales | Perfluorocarbon Emulsions | |
| Hogan et al. | Peter E. Keipert, ¹ N. Simon Faithfull, ¹ JoAnn D. Bradley, 1 Diane Y. Hazard |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071204 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071227 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080501 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080624 |